These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2959046)

  • 21. [Redistribution of the coronary blood flow, functional improvement of the ischemic myocardium and reduction of the size of an experimental infarction by molsidomine].
    Berdeaux A; Giudicelli JF
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):511-5. PubMed ID: 6364947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergized activation of human platelets by epinephrine and platelet-activating factor-acether is adenosine diphosphate and thromboxane A2-independent.
    Vargaftig BB; Fouque F; Joseph D; Odiot J; Benveniste J
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():429-33. PubMed ID: 6221558
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T; Morishima Y; Watanabe K; Takahashi M; Shibano T
    Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
    Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
    J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB; Araki H; Lefer AM
    Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of platelet 5-HT secretion and of 5-HT induced vasoconstriction by paracetamol.
    Verheggen R; Schrör K
    Prog Clin Biol Res; 1987; 242():271-6. PubMed ID: 3671387
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysis of the biological activity of azoprostanoids in human platelets.
    Gorman RR; Shebuski RJ; Aiken JW; Bundy GL
    Fed Proc; 1981 May; 40(7):1997-2000. PubMed ID: 7014259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
    J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists.
    Radomski M
    Acta Physiol Pol; 1985; 36(3):153-64. PubMed ID: 3915630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Platelet aggregation and PAF-acether. Pharmacologic interference].
    Vargaftig BB; Fouque F; Lefort J
    J Pharmacol; 1984; 15 Suppl 1():69-84. PubMed ID: 6374298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Stenocardia: coronary atherosclerosis, coronary spasm, microcirculatory disorders].
    Nikitin GA; Kuznetsov AB; Godin VA
    Vestn Akad Med Nauk SSSR; 1985; (9):82-7. PubMed ID: 3904266
    [No Abstract]   [Full Text] [Related]  

  • 32. Patency of saphenous veins used for aortocoronary bypass grafting: effects of platelet-derived mediators.
    Chiavarelli M; Fabi F; Chiavarelli R; Toscano M; Carpi A; Marino B
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():311-4. PubMed ID: 3159217
    [No Abstract]   [Full Text] [Related]  

  • 33. Constitutional thrombocytopathy with subnormal response to thromboxane A2.
    Samama M; Lecrubier C; Conard J; Hotchen M; Breton-Gorius J; Vargaftig B; Chignard M; Lagarde M; Dechavanne M
    Br J Haematol; 1981 Jun; 48(2):293-303. PubMed ID: 7195274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanisms of thrombocyte aggregation in experimental hypoparathyroidism].
    Chursina IuIa; Amroian EA; Khudaverdian DN
    Biull Eksp Biol Med; 1986 Dec; 102(12):666-8. PubMed ID: 3801615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and experimental study on anti-platelet aggregation effect of d-catechin].
    He YS
    Zhong Xi Yi Jie He Za Zhi; 1982 Jan; 2(1):15-8. PubMed ID: 6219793
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Cyclosporine A nephrotoxicity the role of thromboxane A2.
    Prostaglandins Leukot Essent Fatty Acids; 1988; 33(3):253-5. PubMed ID: 3237735
    [No Abstract]   [Full Text] [Related]  

  • 37. The molecular, biochemical and human pharmacology of thromboxane A2 in renal disease.
    FitzGerald GA; Murray R; Price P; Catella F
    Adv Exp Med Biol; 1989; 259():325-60. PubMed ID: 2516412
    [No Abstract]   [Full Text] [Related]  

  • 38. Thromboxane A2 Mediates Hemodynamic and Respiratory Dysfunction in Graded Bacteremia.
    Slotman GJ
    Surgery; 1989 Jun; 105(6):810-1. PubMed ID: 2727905
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibitory effect of a selective thromboxane A2 receptor antagonist, EP 092, on platelet aggregation in whole blood ex vivo and in vivo.
    Booth RF; Honey AC; Lad N; Tuffin DP; Wade PJ
    Br J Pharmacol; 1989 Feb; 96(2):395-405. PubMed ID: 2522336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of tubuloglomerular feedback in the rat by thromboxane mimetic. Role of macula densa.
    Welch WJ; Wilcox CS
    J Clin Invest; 1992 Jun; 89(6):1857-65. PubMed ID: 1601993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.